BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 8931935)

  • 1. Computational and molecular modeling evaluation of the structural basis for tubulin polymerization inhibition by colchicine site agents.
    ter Haar E; Rosenkranz HS; Hamel E; Day BW
    Bioorg Med Chem; 1996 Oct; 4(10):1659-71. PubMed ID: 8931935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative molecular field analysis of colchicine inhibition and tubulin polymerization for combretastatins binding to the colchicine binding site on beta-tubulin.
    Brown ML; Rieger JM; Macdonald TL
    Bioorg Med Chem; 2000 Jun; 8(6):1433-41. PubMed ID: 10896120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Podophyllotoxin, steganacin and combretastatin: natural products that bind at the colchicine site of tubulin.
    Sackett DL
    Pharmacol Ther; 1993 Aug; 59(2):163-228. PubMed ID: 8278462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The interaction of the B-ring of colchicine with alpha-tubulin: a novel footprinting approach.
    Chaudhuri AR; Seetharamalu P; Schwarz PM; Hausheer FH; Ludueña RF
    J Mol Biol; 2000 Nov; 303(5):679-92. PubMed ID: 11061968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative structure-activity relationship (5D-QSAR) study of combretastatin-like analogues as inhibitors of tubulin assembly.
    Ducki S; Mackenzie G; Lawrence NJ; Snyder JP
    J Med Chem; 2005 Jan; 48(2):457-65. PubMed ID: 15658859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combretastatin-like chalcones as inhibitors of microtubule polymerisation. Part 2: Structure-based discovery of alpha-aryl chalcones.
    Ducki S; Mackenzie G; Greedy B; Armitage S; Chabert JF; Bennett E; Nettles J; Snyder JP; Lawrence NJ
    Bioorg Med Chem; 2009 Nov; 17(22):7711-22. PubMed ID: 19837594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study.
    Lin CM; Singh SB; Chu PS; Dempcy RO; Schmidt JM; Pettit GR; Hamel E
    Mol Pharmacol; 1988 Aug; 34(2):200-8. PubMed ID: 3412321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and antimicrotubule activity of combretatropone derivatives.
    Janik ME; Bane SL
    Bioorg Med Chem; 2002 Jun; 10(6):1895-903. PubMed ID: 11937347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach.
    Nguyen TL; McGrath C; Hermone AR; Burnett JC; Zaharevitz DW; Day BW; Wipf P; Hamel E; Gussio R
    J Med Chem; 2005 Sep; 48(19):6107-16. PubMed ID: 16162011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural and biochemical comparison of the anti-mitotic agents colchicine, combretastatin A4 and amphethinile.
    McGown AT; Fox BW
    Anticancer Drug Des; 1989 Mar; 3(4):249-54. PubMed ID: 2930627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization.
    Cushman M; Nagarathnam D; Gopal D; Chakraborti AK; Lin CM; Hamel E
    J Med Chem; 1991 Aug; 34(8):2579-88. PubMed ID: 1875350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applying linear interaction energy method for binding affinity calculations of podophyllotoxin analogues with tubulin using continuum solvent model and prediction of cytotoxic activity.
    Alam MA; Naik PK
    J Mol Graph Model; 2009; 27(8):930-43. PubMed ID: 19286405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxalone and lactone moieties of podophyllotoxin exhibit properties of both the B and C rings of colchicine in its binding with tubulin.
    Gupta S; Das L; Datta AB; Poddar A; Janik ME; Bhattacharyya B
    Biochemistry; 2006 May; 45(20):6467-75. PubMed ID: 16700557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and biological evaluation of novel tubulin inhibitors as antimitotic agents using a pharmacophore binding model with tubulin.
    Kim DY; Kim KH; Kim ND; Lee KY; Han CK; Yoon JH; Moon SK; Lee SS; Seong BL
    J Med Chem; 2006 Sep; 49(19):5664-70. PubMed ID: 16970393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent colchicine-site ligands with improved intrinsic solubility by replacement of the 3,4,5-trimethoxyphenyl ring with a 2-methylsulfanyl-6-methoxypyridine ring.
    Álvarez R; Aramburu L; Gajate C; Vicente-Blázquez A; Mollinedo F; Medarde M; Peláez R
    Bioorg Chem; 2020 May; 98():103755. PubMed ID: 32200330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis of alkoxy-substituted diaryl compounds and correlation of ring separation with inhibition of tubulin polymerization: differential enhancement of inhibitory effects under suboptimal polymerization reaction conditions.
    Getahun Z; Jurd L; Chu PS; Lin CM; Hamel E
    J Med Chem; 1992 Mar; 35(6):1058-67. PubMed ID: 1552500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the size adaptability of the B ring binding zone of the colchicine site of tubulin with para-nitrogen substituted isocombretastatins.
    Jiménez C; Ellahioui Y; Álvarez R; Aramburu L; Riesco A; González M; Vicente A; Dahdouh A; Ibn Mansour A; Jiménez C; Martín D; Sarmiento RG; Medarde M; Caballero E; Peláez R
    Eur J Med Chem; 2015 Jul; 100():210-22. PubMed ID: 26092446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p,p-Dihydroxydihydrostilbenophanes related to antimitotic combretastatins. Conformational analysis and its relationship to tubulin inhibition.
    Álvarez R; López V; Mateo C; Medarde M; Peláez R
    J Org Chem; 2014 Aug; 79(15):6840-57. PubMed ID: 24966024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Masked Polar Group Incorporation (MPGI) Strategy in Drug Design: Effects of Nitrogen Substitutions on Combretastatin and Isocombretastatin Tubulin Inhibitors.
    González M; Ellahioui Y; Álvarez R; Gallego-Yerga L; Caballero E; Vicente-Blázquez A; Ramudo L; Marín M; Sanz C; Medarde M; Pelaéz R
    Molecules; 2019 Nov; 24(23):. PubMed ID: 31779228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel orally active microtubule destabilizing agent S-40 targets the colchicine-binding site and shows potent antitumor activity.
    Du T; Lin S; Ji M; Xue N; Liu Y; Zhang Z; Zhang K; Zhang J; Zhang Y; Wang Q; Sheng L; Li Y; Lu D; Chen X; Xu H
    Cancer Lett; 2020 Dec; 495():22-32. PubMed ID: 32931884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.